Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | EYA2 | O00167 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13261104 | 1.00 | KDM4E (0.48) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL13261102 | 0.96 | TDP1 (0.43) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL13177612 | 0.93 | TDP1 (0.50) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL13060101 | 0.91 | TDP1 (0.58) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL22053950 | 0.91 | TDP1 (0.58) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL13589811 | 0.89 | KDM4E (0.48) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL2445778 | 0.89 | TDP1 (0.48) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL700291 | 0.89 | TDP1 (0.62) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL7587742 | 0.89 | TDP1 (0.54) | KDM4ETDP1TSHRCYP2C19BLM | |
| SCHEMBL19088206 | 0.88 | TDP1 (0.40) | KDM4ETDP1TSHRCYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464958-B2 | Method for the synthesis of alpha-aminoalkylenephosphonic acid | MONSANTO TECHNOLOGY LLC (US) | 2019-11-05 | — | — | US | claimed |
| US-20180346497-A1 | METHOD FOR THE SYNTHESIS OF ALPHA-AMINOALKYLENEPHOSPHONIC ACID | MONSANTO TECHNOLOGY LLC (US) | 2018-12-06 | — | — | US | claimed |
| US-20150232493-A1 | METHOD FOR THE SYNTHESIS OF ALPHA-AMINOALKYLENEPHOSPHONIC ACID | MONSANTO TECHNOLOGY LLC | 2015-08-20 | — | — | US | claimed |
| US-8124756-B2 | Method of preparing 5′-amino-linker oligonucleotides derivatives and analogous 5′-labeled-linker oligonucleotides therefrom | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2012-02-28 | — | — | US | claimed |
| US-20100093994-A1 | REPARATION METHOD OF AN AMINO LINKER OLIGONUCLEOTIDES AND LABELED-LINKER OLIGONUCLEOTIDE THEREFROM | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2010-04-15 | — | — | US | claimed |
| US-20080267882-A1 | Multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide; positron emission tomography; angiogenesis; kits | STANFORD UNIVERSITY (US) | 2008-10-30 | — | — | US | claimed |
| CN-106061508-B | Oligopeptides and methods of producing oligopeptide conjugates | 豪夫迈－罗氏公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-105916879-B | Camelidae single domain antibodies against amyloid β and methods for producing conjugates thereof | 豪夫迈－罗氏公司 | 2020-07-03 | — | — | CN | disclosed |
| US-10464958-B2 | Method for the synthesis of alpha-aminoalkylenephosphonic acid | MONSANTO TECHNOLOGY LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180346497-A1 | METHOD FOR THE SYNTHESIS OF ALPHA-AMINOALKYLENEPHOSPHONIC ACID | MONSANTO TECHNOLOGY LLC (US) | 2018-12-06 | — | — | US | disclosed |
| US-9808523-B2 | Methods for treatment of brain injury utilizing biologics | TACT IP LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-9694091-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2635283-B1 | METHODS FOR TREATMENT OF BRAIN INJURY UTILIZING BIOLOGICS | TACT IP LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20100093994-A1 | REPARATION METHOD OF AN AMINO LINKER OLIGONUCLEOTIDES AND LABELED-LINKER OLIGONUCLEOTIDE THEREFROM | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2010-04-15 | — | — | US | disclosed |
| US-7666390-B2 | DTPA derivatives and metal complexes thereof, and radiation source and contrast agent including the metal complexes | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2010-02-23 | — | — | US | disclosed |
| US-20100015058-A1 | RADIOLABELED BBN-RGD HETERODIMERS FOR CANCER TARGETING | STANFORD UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-20080267882-A1 | Multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide; positron emission tomography; angiogenesis; kits | STANFORD UNIVERSITY (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080031815-A1 | Pet imaging of vascular endothelial growth factor receptor (VEGFR), compositions for VEGF cancer imaging, and methods of VEGF cancer imaging | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-02-07 | — | — | US | disclosed |
| US-20060251583-A1 | DTPA derivatives and metal complexes thereof, and radiation source and contrast agent including the metal complexes | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2006-11-09 | — | — | US | disclosed |
| EP-1719754-A1 | DTPA derivatives and metal complexes therof, and radiation source and contrast agent including the metal complexes | Korea Atomic Energy Research Institute (KR) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060251583-A1 | DTPA derivatives and metal complexes thereof, and radiation source and contrast agent including the metal complexes | SLC39A11, REN, SLC39A14 | KDM4E 4281/4885TDP1 4522/4885TSHR 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.